Targeting ATM pathway for therapeutic intervention in cancer

Authors:
  • HKHilal S. Khalil
    Hilal S. Khalil
  • HTHemanth Tummala
    Hemanth Tummala
  • SCStoyan Chakarov
    Stoyan Chakarov
  • DLDavid P. Lane
    David P. Lane

Abstract
DNA repair is an essential physiological mechanism for maintaining genomic integrity in nucleated cells. The DNA damage response (DDR) pathway has evolved to be a complex, sensitive, highly integrated and interconnected pathway which can trigger a variety of cellular responses including DNA repair, cell cycle arrest and apoptosis [1]. Central to the DDR is the Ataxia telangiectasia mutated (ATM) gene product, a large protein kinase, which is responsible for the initiation of a signalling cascade that is triggered following double stranded DNA damage. The importance of the role of ATM is highlighted by its functional loss in the disease Ataxia Telangiectasia (A-T), also known as Louis-Barr syndrome, caused by hereditary mutations in the ATM gene. A-T is a rare autosomal recessive disorder characterized by immune deficiency, hypersensitivity to ionizing radiation (IR), and a predisposition to certain cancers [2]. A-T patients usually exhibit only partial deficiency of ATM protein, the residual levels varying between 1 and 17% of the normal level of ATM [3]. Usually, affected individuals present in early childhood with progressive cerebellar ataxia, which may initially be misdiagnosed as cerebral palsy of the ataxic type. Later, conjunctival telangiectasias and immune disturbances develop. Progressive neurological degeneration (without mental retardation) affects a significant proportion of older patients [4]. Thymus hypoplasia and complete loss or severe reduction in IgG2 or IgA levels are seen in the majority of patients. Recurrent sinopulmonary infections, related to the accompanying immune deficiency and gonadal dysgenesis are also common among A-T patients [3, 5]. Predisposition to malignancy, especially haematological cancers, is one of the hallmarks of the A-T syndrome with cancer being the most frequent cause of death of A-T patients. This link between A-T and some forms of cancer was first observed by Reed WB et al in 1966 [7] who looked at incidences of familial and sporadic cancers in homozygous A-T patients as well as in heterozygous carriers. Normally, lymphomas in A-T patients tend to be of B-cell origin, whereas the leukemias are of T-cell origin [8]. Association between A-T status and susceptibility to cancer has been found in a variety of tumours to differing degrees and appears to be dependent on the type of ATM mutation, e.g. missense variants or truncating mutations [9] as well as the nature of the mutations e.g. germ line or somatic A-T [10, 11] At the cellular level, cultured A-T cells are abnormally resistant to inhibition of DNA synthesis by IR [6]. It is notable that heterozygous carriers of ATM mutation are relatively common amongst the general population, with estimates varying between 1.4 % and 2.2 %, and as high as 12.5 % in populations with a marked founder effect [5, 12, 13]. A-T patients from non-consanguineous families are usually compound heterozygotes. Carriers of defective ATM alleles, although generally considered asymptomatic, have been found to have an increased risk of death at any age due to all causes including cancer and ischemic heart disease [5, 13]. The role of defective ATM alleles has been clearly demonstrated in a proportion of familial breast cancer and colorectal cancer cases [14, 15]. Despite the heterogeneity in the clinical presentation of the A-T syndrome resulting in the initial finding of at least 4 complementation groups [16], subsequent linkage analysis showed that they all map to the same genomic location on chromosome 11 (11q22.3) containing the ATM gene [17, 18]. The ATM gene is extremely large - the full genomic region spans 150 Kb and consists of 66 exons [19]. ATM shares a bidirectional promoter with a gene called NPAT, which is located around 0.55 kB upstream of the ATM start codon. NPAT is required for progression through G1/S and entry into S-phase of cell cycle and has also been shown to positively regulate ATM [20, 21]. The ATM promoter region has been found to be TATA-less, but includes CCAAT boxes and several other important promoter sites including CREB, SP1, AP-2, GCF [22, 23, 24]. However, there is some evidence of the existence of another putative promoter region immediately upstream of the first coding exon which includes a TATA box [25]. This may contribute to the basal level expression of the ATM. In the past, several groups, including our own, have analysed the ATM promoter region to study its transcriptional activity and to elucidate ATM expression patterns and have found that the promoter activity is tissue specific, and inducible under certain conditions. For example, Gueven N et al in 2001 [26] reported downregulation of ATM expression upon treatment with Epidermal Growth Factor, while Hirai Y et al [27] in the same year demonstrated upregulation of ATM gene expression upon irradiation of lymphoblastoid cell lines. Recently, we reported induction of ATM expression upon inhibition of its kinase activity [28, 29]. Additional studies in vivo and in vitro as well as computer-aided mathematical modeling studies on ATM also revealed that ATM regulation could be tissue dependent, and may be subject to significant transcriptional regulation both at the promoter and mRNA level [30, 31, 32, 33]. The ATM gene encodes a Serine/Threonine protein kinase belonging to the PhosphatidyInositol 3 K inase like Kinase (PIKK) super family. The ATM protein is a ~350kD nuclear protein comprised of 3056 amino acids [34, 35] with its kinase activity located within the Phosphatidylinositol 3/4 catalytic domain and a FRAP-ATM-TRRAP (FAT) domain located towards the C-terminus (FATC) [35]. A leucine zipper motif has also been identified in the region spanning residues 1217 to 1238, which is thought to be involved in protein-protein interactions [36]. ATM is generally regarded as constitutively expressed protein and is held in an inactive homodimeric or higher order multimeric form. Upon DNA damage, for example by IR treatment, the pre-existing homodimeric ATM complexes undergo rapid autophosphorylation at residues Ser367, Ser1893 and Ser1981 within the FAT domain. This leads to dimer dissociation and the release of the active ATM monomers without an absolute increase in total ATM protein levels [37]. A complete list of known phosphorylated residues of ATM is given in Table 1. However, of those listed, only the autophosphorylation sites at Serine 367, 1893 and 1981 have been fully characterised and play a role in ATM activation [37, 38, 39]. The remainder of the phosphorylation sites were identified through large scale proteomic analysis [40, 41, 42] and their role in regulating the function of the protein warrants further study. Once activated, ATM and other members of the PIKK family phosphorylate key substrates involved in DNA damage repair, DNA replication, cell cycle checkpoint arrest and apoptosis [43, 44], providing an important functional link between DNA damage recognition and appropriate cellular response to the damage.. In terms of its role in cell cycle regulation, ATM interacts with a number of downstream substrates including proteins that activate the G1, S or G2/M checkpoints, as set out in Table 2. This functional link between the two pathways is very specific and tightly regulated at multiple levels. A simplified version of this pathway is shown in Figure 1. DNA damage activates sensor proteins and transducers that recognize, relay and amplify the damage signal following genotoxic insult, and triggers different cellular responses depending on the level of DNA damage. ATM also has a critical role in homologous repair during normal meiotic recombination events [45]. Several early studies reported no quantitative changes in the expression levels and localisation of ATM throughout the cell cycle and upon DNA damage [47, 48]. However later studies reported that under certain conditions the expression of ATM may be altered, accompanied by a corresponding change in ATM activity [26, 32, 49].